Medical Use of Cannabis in 2019.

Authors: Kevin P. Hill
JAMA, 9 August 2019

Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the…

A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes.

Authors: Lynda G. Balneaves, Abeer Alraja, Daniel Ziemianski, Fairleth McCuaig, Mark Ware
Cannabis and Cannabinoid Research, March 2018

Introduction: In Canada, the Access to Cannabis for Medical Purposes Regulations (ACMPR) has given nurse practitioners (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This expansion in NPs’ scope of practice underscores the importance…

Physicians-in-training are not prepared to prescribe medical marijuana.

Authors: Anastasia B. Evanoff, Tiffany Quan, Carolyn Dufault, Michael Awad, Laura Jean Bierut
Drug and Alcohol Dependence, 1 November 2017

BACKGROUND: While medical marijuana use is legal in more than half of U.S. states, evidence is limited about the preparation of physicians-in-training to prescribe medical marijuana. We asked whether current medical school and graduate medical educational training prepare phys…

Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.

Authors: Deborah S. Hasin, Melanie Wall, Katherine M. Keyes, Magdalena Cerdá, John Schulenberg, et al
The Lancet Psychiatry, July 2015

BACKGROUND: Adolescent use of marijuana is associated with adverse later effects, so the identification of factors underlying adolescent use is of substantial public health importance. The relationship between US state laws that permit marijuana for medical purposes and adoles…

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors: Ryan Vandrey, Jeffrey C. Raber, Mark E. Raber, Brad Douglass, Cameron Miller, Marcel O. Bonn-Miller
JAMA, 23 June 2015

As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-…

Medical Marijuana: Is the Cart Before the Horse?

Authors: Deepak Cyril D’Souza, Mohini Ranganathan
JAMA, 23 June 2015

There is a pressing need to develop new medications for many debilitating conditions. Novel approaches based on marijuana or its constituent cannabinoids, if proven, could be added to the armamentarium of available treatments. In this issue of JAMA, reviews by Whiting et al1 a…

Current Status and Future of Cannabis Research

Authors: Ethan B. Russo, Alice P. Mead, Dustin Sulak
Clinical Researcher, April 2015

Although cannabis is primarily viewed by the public as a recreational drug or agent of abuse, its medical application spans recorded history.1,2 Evolution has yielded a cannabis plant that produces a family of some 100 chemicals called phytocannabinoids (“plant cannabinoids”)…

The impact of marijuana policies on youth: clinical, research, and legal update.

Authors: COMMITTEE ON SUBSTANCE ABUSE, COMMITTEE ON ADOLESCENCE
Pediatrics, March 2015

This policy statement is an update of the American Academy of Pediatrics policy statement “Legalization of Marijuana: Potential Impact on Youth,” published in 2004. Pediatricians have special expertise in the care of children and adolescents and may be called on to advise legi…

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders.

Authors: Barbara S. Koppel, John C.M. Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, et al
Neurology, 29 April 2014

OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We gra…